KCK-based Cingulate hires a top legal officer as it enters the home stretch of its effort to win FDA approval for a new drug.

Company News Published 05/14/2025, 08:13 AM 0 Cingulate receives FDA meeting feedback on ADHD drug CING -1.38% ...

Cingulate has a 52 week low of $1.80 and a 52 week high of $20.83. The firm’s 50-day simple moving average is $4.01 and its 200 day simple moving average is $4.32. Hedge Funds Weigh In On Cingulate ...

$ (108,489,180 ) $ (92,943,443 ) Total stockholders' equity $ 7,455,504 $ (6,869,429 ) Cingulate Inc. Consolidated Statements of Operations Three Months Ended December 31, Year Ended December 31, 2024 ...

Fintel reports that on November 20, 2024, Maxim Group upgraded their outlook for Cingulate (NasdaqCM:CING) from Hold to Buy. Analyst Price Forecast Suggests 1,729.02% Upside As of October 22, 2024 ...

Maxim upgraded Cingulate (CING) to Buy from Hold with an $8 price target Don't Miss our Black Friday Offers:Unlock your investing potential with TipRanks Premium - Now At 40% OFF!Make smarter ...

Second, the cingulotomy rests on no firmer scientific foundation than lobotomy did. First performed in 1952 as a modified version of the lobotomy, cingulotomy was based on Freeman’s observations that ...

Cingulate Inc. (Nasdaq: CING) has started the last study it needs before submitting its drug, a precision-timed release ADHD medication, for Food and Drug Administration approval, according to a ...

Cingulate Inc. (NASDAQ: CING) shares are on an upward trajectory Friday. It follows the announcement that Cingulate has been granted European Patent No. 3261625 for its flagship asset, CTx-1301 ...

Cingulate's stock surges over 159% after being granted a European patent for its lead ADHD treatment asset, CTx-1301. CTx-1301 is designed to deliver three timed releases of medication throughout ...

KANSAS CITY, Kan., Aug. 15, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform ...